Main Article Content
Objective To identify the appropriate parameters for calculating disease burden of alcohol use disorders (AUD) and drug use disorders (DUD).
Material and method The literatures were searched through MEDLINE database and Google Scholar, using relevant keywords. Literatures published after the 1997 were identified and subsequently screened for relevancy to the study. Finally, full-text publications were systematically reviewed and
synthesized according to each subtopic.
Results One-year prevalence of AUD and DUD were between 0.2%-4.6% and 0.0%-2.0% respectively. Individuals with AUD were mostly in moderate categories while persons with DUD were largely in moderate and severe categories. The age of onset of AUD and DUD were between 14.0-30.5
years and 15.0-24.7 years, with duration of each episode between 1.8-3.7 years and 1.6-4.3 years, and remission rate at one year after onset between 34%-89% and 5%-45% respectively. Relative risk of mortality among individuals with AUD was 1.8-4.6, compared to those without disorders, while mortality
rate among those with DUD was 3.2-18.6 folds of general population.
Conclusion Prevalence and age of onset of AUD and DUD are available in Thailand and comparable to international studies, thus should be used for disease burden estimation. The future research should be focused on other parameters that are not yet available in Thailand.
- Authorization to photocopy items for internal or personal use of specific clients, is granted. The consent does not extend to other kinds of copying, such as for general distribution, for advertising, or for resale.
- Unless otherwise states, the views and opinion expressed in Journal of Mental Health of Thailand are those of authors of the papers, and do not represent those of the editorial board or the Department of Mental Health.
2. Kassebaum NJ, Arora M, Barber RM, Bhutta ZA, Brown J, Carter A, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet 2016;388:1603-58.
3. Burden of disease Thailand working group. Disability – adjusted life yeas (DALYs) 2014. Nonthaburi: International Health Policy Program, Ministry of Public Health; 2017. (in Thai)
4. Kittirattanapaiboon P, Tantirangsee N, Chutha W, Tanaree A, Kwansanit P, Assanangkornchai S. Prevalence of mental
disorders and mental health problems: Thai national mental health survey 2013. Journal of Mental Health of Thailand 2017;25:1-19.(in Thai)
5. Kessler RC, Üstün TB. The world mental health (WMH) survey initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 2004;13:93-121.
6. Haro JM, Arbabzadeh-Bouchez S, Brugha TS, De Girolamo G, Guyer ME, Jin R, et al. Concordance of the Composite
International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO world mental health surveys. Int J Methods Psychiatr Res 2006;15:167-80.
7. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005;62:617-27.
8. Bijl RV, Ravelli A, Van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands mental health survey and Incidence study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol 1998;33:587-95.
9. Andrews G, Henderson S, Hall W. Overview of the Australian national mental health survey. Prevalence, comorbidity, disability and service utilisation. Br J Psychiatry 2001;178:145-53.
10. Williams D, Herman A, Stein D, Heeringa S, Jackson P, Moomal H, et al. Twelve-month mental disorders in South Africa: prevalence, service use and demographic correlates in the population-based South African stress and health study. Psychol Med 2008;38:211-20.
11. Shen YC, Zhang MY, Huang YQ, He YL, Liu ZR, Cheng H, et al. Twelve-month prevalence, severity, and unmet need for treatment of mental disorders in metropolitan China. Psychol Med 2006;36:257-67.
12. Kawakami N, Takeshima T, Ono Y, Uda H, Hata Y, Nakane Y, et al. Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan: preliminary finding from the world mental health Japan survey 2002–2003. Psychiatry Clin Neurosci 2005;59:441-52.
13. Cho MJ, Chang SM, Lee YM, Bae A, Ahn JH, Son J, et al. Prevalence of DSM-IV major mental disorders among Korean adults: a 2006 national epidemiologic survey (KECA-R). Asian J Psychiatry 2010;3:26-30.
14. Chong SA, Abdin E, Vaingankar JA, Heng D, Sherbourne C, Yap M, et al. A population-based survey of mental disorders in Singapore. Ann Acad Med Singapore 2012;41:49-66.
15. Gureje O, Lasebikan VO, Kola L, Makanjuola VA. Lifetime and 12-month prevalence of mental disorders in the Nigerian survey of mental health and well-being. Br J Psychiatry 2006;188:465-71.
16. Andrews G, Henderson S, Hall W. Prevalence, comorbidity, disability and service utilisation. Br J Psychiatry 2001;178:145-53.
17. Slade T, Johnston A, Oakley Browne MA, Andrews G, Whiteford H. 2007 National survey of mental health and Wellbeing: methods and key findings. Aust N Z J Psychiatry 2009;43:594-605.
18. Ishikawa H, Kawakami N, Kessler R. Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in Japan: results from the final dataset of world mental health Japan survey. Epidemiol Psychiatr Sci 2016;25:217-29.
19. Burstein R, Fleming T, Haagsma J, Salomon JA, Vos T, Murray CJ. Estimating distributions of health state severity for the global burden of disease study. Popul Health Metr 2015;13:31.
20. Behrendt S, Wittchen H-U, Höfler M, Lieb R, Beesdo K. Transitions from first substance use to substance use disorders in adolescence: is early onset associated with a rapid escalation? Drug Alcohol Depend 2009;99:68-78.
21. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2007;64:830-42.
22. Rehm J, Dawson D, Frick U, Gmel G, Roerecke M, Shield KD, et al. Burden of disease associated with alcohol use disorders in the United States. Alcohol Clin Exp Res 2014;38:1068-77.
23. Wu LT, Woody GE, Yang C, Mannelli P, Blazer DG. Differences in onset and abuse/dependence episodes between prescription opioids and heroin: results from the national epidemiologic survey on alcohol and related conditions. Subst Abuse Rehab 2011;2:77.
24. De Bruijn C, Van Den Brink W, De Graaf R, Vollebergh WA. The three year course of alcohol use disorders in the general population: DSM-IV, ICD-10 and the craving withdrawal model. Addiction 2006;101:385-92.
25. Hasin DS, Van Rossem R, McCloud S, Endicott J. Differentiating DSM-IV alcohol dependence and abuse by course: community heavy drinkers. J Subst Abuse 1997;9:127-35.
26. Dawson DA, Grant BF, Stinson FS, Chou PS, Huang B, Ruan W. Recovery from DSM-IV alcohol dependence: United States, 2001–2002. Addiction 2005;100:281-92.
27. Moos RH, Moos BS. Long-term influence of duration and intensity of treatment on previously untreated individuals with alcohol use disorders. Addiction 2003;98:325-38.
28. Calabria B, Degenhardt L, Briegleb C, Vos T, Hall W, Lynskey M, et al. Systematic review of prospective studies investigating “remission” from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav 2010;35:741-9.